drugset / Trial / NCT02022215

Efficacy and Safety Study of ME1111 in Patients With Onychomycosis

NCT02022215 ↗

Phase 2 Completed 304 enrolled Meiji Seika Pharma Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to determine the safety and efficacy of high and low strength of ME1111 solutions compared to the vehicle in the treatment of onychomycosis of the toenail.

Timeline

Start
2013-12-19
Primary completion
2015-10-28
Completion
2016-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ME1111 Unknown — —

Indications